Abstract

Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call